Relmada Q2 2026: $217.7M Cash Fuels Pipeline Through 2029 as Year-End IND Filings Loom
RLMD has more than doubled off its 52-week low of $0.55.
Summary
Relmada Therapeutics reported Q2 2026 financial results with $217.7M in cash, sufficient to fund operations through 2029. The company confirmed year-end 2026 IND filings for lead programs NDV-01 and sepranolone, with pivotal trials to start upon FDA clearance.
Key Events · Earnings and Guidance · RLMD
-
Q2 2026 Financial Results
Net loss of $12.9M ($0.11/share) on R&D spend of $8.4M and G&A of $6.6M. Cash, equivalents, and short-term investments totaled $217.7M as of June 30, 2026.
-
Cash Runway Through 2029
Management expects current cash to fund operations through 2029, including completion of the NDV-01 Phase 3 RESCUE program, removing near-term financing risk.
-
NDV-01 IND Filing by Year-End 2026
Manufacturing and CMC activities ongoing; IND submission expected by YE26 with Phase 3 RESCUE registrational program initiation upon FDA clearance.
-
Sepranolone IND Filing by Year-End 2026
Formulation complete, pre-filled syringe delivery system being finalized; IND expected by YE26, followed by Phase 2 proof-of-concept study in Prader-Willi Syndrome.
Analysis · RLMD · Life Sciences
With $217.7 million in cash, Relmada's Q2 update extends its runway through 2029, fully funding the pivotal Phase 3 RESCUE program for NDV-01. The net loss widened to $12.9 million as R&D spending ramped for manufacturing and IND-enabling work, yet the balance sheet remains robust after recent financings. Key catalysts are now clearly defined: IND filings for both NDV-01 and sepranolone by year-end 2026, with Phase 3 and Phase 2 initiations upon clearance. Further de-risking the execution story are the addition to the Russell indexes and the appointment of a Chief Business Officer with direct NMIBC commercial experience. For a clinical-stage biotech, this level of cash visibility and regulatory alignment is a meaningful positive signal.
At the time of this filing, RLMD was trading at $5.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $563.3M. The 52-week trading range was $0.55 to $8.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.